AstraZeneca Pharma India announces marketing approval for Tagrisso (Osimertinib)

AstraZeneca Pharma India Limited announced that it has received marketing approval for Tagrisso (Osimertinib) for adjuvant treatment after complete tumour resection in patients with non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) mutations According to the Global Cancer Survey (GLOBOCAN), in 2018, the total number of new Lung cancer cases were 67,795 & 63,475 deaths were reported, making lung cancer a very aggressive and devastating cancer. It has also been estimated that by 2020, India would have around ~ 89,000 new  Lung Cancer cases